- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Nexavar ( Sorafenib )
Nexavar (sorafenib) is a multikinase inhibitor indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally advanced or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine. Sorafenib inhibits multiple intracellular and cell surface kinases, including Raf kinases, VEGFR‑1, VEGFR‑2, VEGFR‑3, PDGFR‑beta, KIT, and FLT‑3, which are involved in tumour cell proliferation and tumour angiogenesis. By blocking these signalling pathways, Nexavar slows tumour growth and reduces tumour vascularization. It is an oral targeted therapy and is not a traditional cytotoxic chemotherapy agent.
Usual adult dose: The recommended dose is 400 mg (two 200 mg tablets) taken orally twice daily, on an empty stomach (at least 1 hour before or 2 hours after a meal). The total daily dose is 800 mg. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. If a dose is missed, the patient should take the next dose at the usual time; two doses must not be taken at the same time. Dose modifications may be required for adverse reactions. For persistent or significant toxicity, treatment may be temporarily interrupted and, when resumed, the dose may be reduced to 400 mg once daily; if further reduction is needed, 400 mg every other day may be considered. In patients with hepatic or renal impairment, no initial dose adjustment is recommended, but close monitoring is advised; in severe hepatic impairment, sorafenib should be used with caution because exposure may be increased. Sorafenib tablets should be swallowed whole with water.
Dosage form: Film‑coated tablets: 200 mg (red, round, biconvex, debossed with "200" on one side and "NAT" on the other). Available in bottles of 120 tablets.
Onset of action: Steady‑state plasma concentrations are reached within 7 days of continuous twice‑daily dosing. Antitumour activity is assessed radiographically after 2 to 3 months of therapy; progression‑free survival benefit varies depending on tumour type and patient characteristics.
Duration of action: The elimination half‑life of sorafenib is approximately 25 to 48 hours, supporting continuous twice‑daily dosing without a drug‑free interval. The pharmacodynamic effect is maintained as long as therapy is continued.
Alcohol recommendation: Alcohol should be avoided during treatment with Nexavar. Alcohol is hepatically metabolized and may compound the risk of liver injury, especially in patients with hepatocellular carcinoma or pre‑existing liver dysfunction. Heavy alcohol intake can also worsen dehydration, gastrointestinal irritation, and impair overall tolerance to the medication.
Most common side effects: Diarrhea, fatigue, hand‑foot skin reaction (palmar‑plantar erythrodysesthesia), rash, alopecia, hypertension, nausea, vomiting, abdominal pain, and loss of appetite. Hand‑foot skin reaction is frequent and can be disabling; patients should be counselled on preventive skin care, including moisturizing, avoiding hot water and friction, and reporting early signs of redness or blistering. Hypertension is a common vascular effect and may require antihypertensive therapy; blood pressure should be monitored weekly during the first 6 weeks of treatment and periodically thereafter. Rare but serious adverse events include cardiac ischemia or myocardial infarction, bleeding, gastrointestinal perforation, wound healing complications, and hepatic failure. Sorafenib can cause QT interval prolongation; caution is required in patients with a history of QT prolongation or those taking other QT‑prolonging drugs. Liver function tests should be monitored regularly, especially in patients with underlying liver disease. Hypothyroidism may occur in patients with thyroid cancer; thyroid function should be checked before and during treatment. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose, as sorafenib may cause fetal harm. Nexavar is available only by prescription and must be initiated and supervised by a healthcare professional experienced in oncology.
Would you like to try Nexavar (Sorafenib) without a prescription?
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
